Offshore Opportunity on the Rise - - BioPharm International


Offshore Opportunity on the Rise

BioPharm International
Volume 21, Issue 3


Preclinical services are not the only areas where Western CROs are expanding in China. Two CROs have recently added central laboratory capacity as the volume of clinical studies there continues to grow.

Quintiles (Research Triangle Park, NC) opened a 7,000-sq. ft. central laboratory in Beijing. The laboratory is part of a new 17,000-sq. ft. facility where Quintiles is consolidating its Beijing clinical research services. The new laboratory is 50% larger than Quintiles's previous operation, which was located at the Peking Union Medical College. The company said the laboratory has 13 employees and is growing.

PPD (Wilmington, NC) is taking over from Quintiles's partnering role with Peking Union Medical College. Under the terms of its agreement with Peking Union Lawke Biomedical Development Limited (PUL), PPD invested in laboratory equipment located at Peking Union Medical College. PPD says the equipment is identical to its other central laboratory locations in Belgium and the US, and that it has crossvalidated assays, making data compatible with that generated at the other laboratories. PUL will conduct chemistry, hematology, urinalysis and hemoglobin A1c, and esoteric tests for PPD and will have rights to use the equipment to conduct central laboratory testing for clients running clinical trials in China.

PPD joins Quintiles and Covance as major CROs with central laboratory operations in China. The PPD statement suggests that owning a central laboratory in China may bestow a significant competitive advantage. According to the company, "Chinese law makes it extremely difficult to export lab samples to other countries for testing," and it will save clients money because they will be able to process samples locally rather than having to export them. If so, owning central laboratory operations in China is more than just an opportunity to grow the business; it marks another opportunity for the largest CROs to differentiate themselves from smaller rivals.

Jim Miller is president of PharmSource Information Services, Inc. , Springfield, VA, 703.383.4903,

blog comments powered by Disqus



Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines
Source: BioPharm International,
Click here